CSIMarket
 


Cellular Biomedicine Group Inc   (CBMG)
Other Ticker:  
 

Cellular Biomedicine Group Inc 's Working Capital Ratio

CBMG's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2020, Working Capital Ratio fell to 0.47 below Cellular Biomedicine Group Inc average.

Within Biotechnology & Pharmaceuticals industry 224 other companies have achieved higher Working Capital Ratio than Cellular Biomedicine Group Inc in third quarter 2020. While Working Capital Ratio total ranking in the third quarter 2020 has deteriorated compared to the prior quarter from 4137 to 4780.

Explain Working Capital Ratio
How much in Current Assets CBMG´s has?
What is the value of CBMG´s Current Liabilities?


CBMG Working Capital Ratio (Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
Y / Y Current Liabilities Change 129.33 % 28.33 % 60.23 % 283.87 % 336 %
Y / Y Current Assets Change -42.2 % -74.8 % -63.78 % -37.68 % -31.46 %
Working Capital Ratio MRQ 0.47 0.53 1 1.44 1.86
CBMG's Total Ranking # 4780 # 4137 # 3189 # 2289 # 2629
Seq. Current Liabilities Change 108.41 % 20.91 % -0.59 % -8.45 % 16.62 %
Seq. Current Assets Change 86.11 % -36.43 % -30.77 % -29.42 % -18.85 %



Working Capital Ratio third quarter 2020 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 225
Healthcare Sector # 929
Overall Market # 4780


Working Capital Ratio Statistics
High Average Low
23.51 5.61 0.01
(Sep 30 2016)   (Sep 30 2012)




Financial Statements
Cellular Biomedicine Group Inc 's Current Liabilities $ 59 Millions Visit CBMG's Balance sheet
Cellular Biomedicine Group Inc 's Current Assets $ 28 Millions Visit CBMG's Balance sheet
Source of CBMG's Sales Visit CBMG's Sales by Geography


Cumulative Cellular Biomedicine Group Inc 's Working Capital Ratio

CBMG's Working Capital Ratio for the trailling 12 Months

CBMG Working Capital Ratio

(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
Y / Y Current Liabilities TTM Growth 129.33 % 28.33 % 60.23 % 283.87 % 336 %
Y / Y Current Assets TTM Growth -42.2 % -74.8 % -63.78 % -37.68 % -31.46 %
Working Capital Ratio TTM 0.74 1.19 1.73 2.39 3.3
Total Ranking TTM # 4756 # 3718 # 3719 # 3716 # 4423
Seq. Current Liabilities TTM Growth 108.41 % 20.91 % -0.59 % -8.45 % 16.62 %
Seq. Current Assets TTM Growth 86.11 % -36.43 % -30.77 % -29.42 % -18.85 %


On the trailing twelve months basis Due to in Current Liabilities in the III Quarter 2020 to $59.30 millions, cumulative Working Capital Ratio decreased to 0.74 below the Cellular Biomedicine Group Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 123 other companies have achieved higher Working Capital Ratio than Cellular Biomedicine Group Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 3718 to 4756.

Explain Working Capital Ratio
How much in Current Assets CBMG´s has?
What is the value of CBMG´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 124
Healthcare Sector # 941
Within the Market # 4756


trailing twelve months Working Capital Ratio Statistics
High Average Low
20.07 7.26 0.74
(Mar 31 2017)   (Sep 30 2020)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2020, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2020 MRQ Current AssetsSep 30 2020 MRQ Current Liabilities
Champions Oncology Inc   1.18 $ 14.990  Millions$ 12.754  Millions
Sorrento Therapeutics Inc   1.15 $ 105.988  Millions$ 92.125  Millions
Titan Pharmaceuticals Inc   1.13 $ 6.649  Millions$ 5.877  Millions
Outlook Therapeutics Inc   1.13 $ 17.944  Millions$ 15.889  Millions
Acorda Therapeutics Inc   1.09 $ 151.814  Millions$ 138.749  Millions
Avalon Globocare Corp   0.88 $ 2.153  Millions$ 2.440  Millions
Cyclo Therapeutics Inc   0.87 $ 3.972  Millions$ 4.546  Millions
Elutia inc   0.87 $ 22.213  Millions$ 25.585  Millions
Kiromic Biopharma Inc   0.87 $ 1.543  Millions$ 1.779  Millions
Agenus Inc  0.85 $ 125.451  Millions$ 146.895  Millions
Cellular Biomedicine Group Inc   0.47 $ 27.871  Millions$ 59.297  Millions
Zeo Scientifix Inc   0.34 $ 0.864  Millions$ 2.540  Millions
Biondvax Pharmaceuticals Ltd   0.17 $ 3.305  Millions$ 19.965  Millions
Gene Biotherapeutics Inc   0.16 $ 0.801  Millions$ 4.927  Millions
Qrons Inc   0.12 $ 0.094  Millions$ 0.793  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com